UMHATEM N.I.Pirogov, Clinic of internal diseases
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Muehler, Andreas
EMPhASIS, NCT03846219 / 2018-001896-19: MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis

Active, not recruiting
2
210
Europe, RoW
IMU-838 (30 mg/day), Vidofludimus Calcium, Oral Tablet (30 mg/day), IMU-838 (45 mg/day), Vidofludimus Calcium, Oral Tablet (45 mg/day), Placebo, IMU-838 (10 mg/day), Vidofludimus Calcium, Oral Tablet (10 mg/day)
Immunic AG
Relapsing-Remitting Multiple Sclerosis (RRMS)
04/20
12/29
CALDOSE-1, NCT03341962 / 2017-003703-22: Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

Hourglass Oct 2021 - Dec 2021 : Top-line data from CALDOSE-1 study in moderate-to-severe ulcerative colitis
Terminated
2
263
Europe, US, RoW
IMU-838, IM90838, vidofludimus calcium, Placebo, Placebo (for IMU-838)
Immunic AG
Ulcerative Colitis
11/22
11/22
ACTRN12620000901909: A three-part, double-blind, placebo-controlled, Phase I/Ib study of the safety, tolerability and pharmacokinetics of single and multiple ascending doses of IMU-856 in healthy volunteers and patients with Celiac disease

Completed
1
120
 
Immunic Australia Pty Ltd, Immunic Australia Pty Ltd
Diarrhea-predominant irritable bowel syndrome, Celiac disease
 
 

Download Options